Myelodysplastic Syndrome
Conditions
Keywords
myelodysplasia, curcumin, coenzyme Q10, cytopenia
Brief summary
To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.
Interventions
DRUGcurcumin; coenzyme q10
Sponsors
Hadassah Medical Organization
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5.
Exclusion criteria
* Pregnant women and nursing women will be excluded. * History of clinically significant liver or kidney disease. * ECOG\>2 * IPSS score \>1.5 * Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major hematologic improvement in any lineage | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to disease progression | — |
| Overall and progression-free survival | — |
| Cytogenetic response | — |
Countries
Israel
Outcome results
None listed